Eli Lilly is making a play for the idiopathic pulmonary fibrosis (IPF) market, offering Mediar Therapeutics $99 million in ...

U.S.-based biotech builder Mountainfield Venture Partners and China’s Keymed Biosciences have launched a new company armed ...

Dan Monahan, the exec who led Otsuka’s commercialization of Rexulti and Abilify Maintena, is taking command of the launch of ...

Armed with $115 million and a clinical-stage asset, another player is emerging in the increasingly crowded T cell engager ...

City Therapeutics has inked a new deal with Bausch + Lomb for a gene silencing approach to the eye disorder geographic ...

Pfizer’s “golden egg” has hatched. The subcutaneous PD-1 inhibitor improved outcomes when added to the standard of care in ...

Intellia Therapeutics is starting off 2025 with a significant head count reduction as it tosses out pipeline assets to keep ...

As recently as last month, the biotech had been setting out plans for a phase 3 trial of the combo treatment for later in ...

Light Horse Therapeutics is off to the races, rounding up a $62 million series A and tacking on a Novartis partnership that ...

Young biotech Dropshot Therapeutics has hooked in Etherna Immunotherapies with an RNA pact that could net up to $950 million.

Illumina has begun rolling out a series of updates to its top-of-the-line DNA sequencer models, with the goal of making the ...

Under the terms of the deal, Alchemab and Lilly will work together on up to five new antibodies, according to a Jan. 9 ...